About this episode

Dr. Ravi K. Amaravadi discusses the evolution of therapies for Stage IV metastatic melanoma and highlights innovations developed at Penn Medicine.

Clinician-researcher Ravi K. Amaravadi, MD, recalls a time within recent memory when no therapies existed for Stage IV metastatic melanoma, and reflects upon the 17 FDA-approved therapies now available to treat the disease. In this podcast, Dr. Amaravadi notes that many of these agents— including molecularly targeted therapy, immunotherapy in solid tumors, TIL cellular therapy, and personalized mRNA cancer vaccines—were pioneered at Penn Medicine. Learn more about Ravi K. Amaravadi, MD

Explore listener stats, chart rankings, contacts and more on the Penn Medicine Physician Interviews podcast page.